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Restenosis Intra-Stent: Balloon Angioplasty Versus Elective
Stenting: Results of a Randomized Trial
A. CEQUIER, J. ZUECO, A. BETHENCOURT,
J. ANGEL, R. MANTILLA, I. CALVO,
J.M. HERNANDEZ, R. MELGARES, N. VAZQUEZ,
J.M. GARCI´A, R. SEABRA, AND F. ALFONSO,
FOR THE RIBS (RESTENOSIS INTRA-STENT:
BALLOON VERSUS STENT THERAPY)
INVESTIGATORS
UNIVERSITARIO SAN CARLOS, MADRID, SPAIN AND PORTUGAL
Background. Restenosis after stent implantation consti-
tutes a clinical challenge. Methods. A prospective, multi-
center, randomized trial comparing balloon angioplasty
(BA) with elective stent implantation for patients with
in-stent restenosis was designed. Randomization was cen-
tralized, with subrandomization for restenosis length. From
December 1997 to December 1999, 450 patients were
randomized (224 stent, 226 BA) at 24 sites in Spain and
Portugal. All patients had symptoms or objective evidence
of ischemia. Results. Mean age was 61 6 11 years, and 101
patients (22%) were women. Baseline clinical and angio-
graphic characteristics were well balanced in the two groups.
Cross-over occurred in three patients allocated to stent
(1.3%) and 13 patients allocated to BA (5.8%). Higher
pressures (13.5 6 2 vs. 12.6 6 2 bar, p , 0.01) were used
in the stent patients. Angiographic success was obtained in
all but two patients. During hospitalization, two patients
died (one patient in each group), 11 developed myocardial
infarction (2 stent patients [0.9%] and 9 BA patients [4%],
p 5 0.06 [relative risk 0.22, 95% confidence interval 0.05 to
1.03]) and one BA patient required elective surgery. On
quantitative coronary angiography analysis (centralized
core-lab), minimal lumen diameter (MLD) before the
procedure was similar (0.7 6 0.4 vs. 0.7 6 0.4 mm), but a
larger final MLD (2.7 6 0.5 vs. 2.2 6 0.4 mm, p , 0.001)
and greater short-term gain (2 6 0.5 vs. 1.5 6 0.5 mm, p ,
0.001) were obtained in stent patients. At late angiography
(415 patients, 95% eligible), MLD was 1.63 6 0.8 mm in
the stent group and 1.52 6 0.7 mm in the BA group (p 5
0.17). Restenosis rates were similar, 38% and 39% for the
stent and BA groups, respectively. Clinical follow-up at
seven months (100% of patients) revealed a similar event-
free survival (80% stent vs. 77% BA). However, in the
pre-specified cohort of patients with large vessels (.23 mm),
the restenosis rate was lower (27% vs. 48%, p , 0.007), and
the event-free survival better (87% vs. 71%, p , 0.01), after
stenting. Conclusions. In patients with in-stent restenosis,
initial results are satisfactory with both techniques, but
recurrent restenosis remains high. Elective stent implanta-
tion provides better short-term angiographic results but fails
to improve the late angiographic outcome. In patients with
large vessels, however, the long-term clinical and angio-
graphic outcome is significantly better after stenting.
Direct Laser Myocardial Revascularization With Biosense™
LV Electromechanical Mapping in Patients With Refractory
Myocardial Ischemia: Final Results of a Blinded Randomized
Clinical Trial
MARTIN B. LEON, DONALD S. BAIM,
JEFFREY W. MOSES, ROGER LAHAM,
WILLIAM KNOPF, MARK REISMAN,
DANIEL MCCORMICK, HOWARD COHEN,
TIMOTHY FISCHELL, BARRY COHEN,
RICHARD E. KUNTZ, AND RAN KORNOWSKI
CARDIOVASCULAR RESEARCH FOUNDATION,
NEW YORK CITY, NEW YORK
Background. Previous studies of direct laser myocardial
revascularization (DMR) using the Biosense™ LV electro-
mechanical mapping system have associated this treatment
with improvements in exercise capacity and reductions of
angina symptoms in patients with refractory myocardial
ischemia. Methods. In 14 centers, a randomized blinded
study comparing placebo (left ventricular mapping without
DMR) and DMR (low- and high-dose) was performed in
298 patients with functional class III/IV angina with six-
month and 12-month follow-up assessments, including
exercise tests, angina symptoms, and radionuclide perfusion
imaging. Results. There were no differences among the
three groups (placebo, low- and high-dose DMR) in exer-
cise duration, exercise time to angina, and exercise time to
ST-segment onset at six months and 12 months. Similarly,
Canadian Cardiovascular Society (CCS) angina and other
quality of life parameters were unchanged during follow-up.
A significant placebo effect was observed, including im-
proved exercise duration at six months and 12 months (p ,
0.033 and 0.057) and .22 class reduction in CCS angina atFrom the University of Virginia, Charlottesville, Virginia.
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six months and 12 months (36% and 41% of patients).
Radionuclide perfusion imaging showed no changes from
baseline to six months (stress and rest) among the groups.
Conclusions. In this blinded randomized trial in patients
with severe refractory angina, treatment with the Biosense™
DMR system resulted in: 1) no improvement in exercise,
angina severity, and radionuclide imaging assessments com-
pared with placebo at six months and 12 months; and 2)
important placebo actions that persisted for 12 months.
Therefore, all future studies in this field should include a
blinded no-treatment group to account for the possibility of
important placebo effects.
COMMENTARY
This blinded, randomized, placebo-controlled study by
Leon and colleagues emphasizes once again that placebo
treatment is often associated with significant isolated im-
provements. That both treatment groups showed no change
in radionuclide markers of ischemia suggests that no bene-
fits in either group were related to myocardial perfusion. By
contrast, the fact that surgical transmyocardial revascular-
ization (TMR) techniques have shown improved perfusion
in some studies (although not universally) suggests that
percutaneous techniques may have limitations relative to the
extent of areas treated or the depth of lesions created, either
or both of which could limit efficacy.
In, summary, more data are needed to demonstrate the
efficacy of TMR, particularly as it affects myocardial perfu-
sion. In addition, a better understanding of the myocardial
effect of local laser applications and how such treatment
might be enhanced by adjunctive therapy is crucially impor-
tant. Short of this, one can only wonder about the signifi-
cant placebo effect seen in these patients.
GEORGE W. VETROVEC
The “Stent or Surgery” Trial (SoS): A Randomized,
Controlled Trial to Compare Coronary Artery Bypass
Grafting (CABG) With Percutaneous Transluminal Coronary
Angioplasty (PTCA) Supported by Stent Implantation
RODNEY H. STABLES
THE CARDIOTHORACIC CENTER, LIVERPOOL,
UNITED KINGDOM
Background. Previous randomized trials comparing
PTCA with surgical revascularization have reported a high
rate of repeat revascularization in the PTCA group. Stents
have reduced restenosis rates in percutaneous coronary
interventions (PCIs). The SoS trial compared two strategies
for coronary revascularization: surgery and PTCA sup-
ported by stent implantation. Methods. The SoS Trial was
a multicenter (53 centers), multinational (Europe and Can-
ada), randomized, controlled trial. Symptomatic patients
with multivessel disease were included if they were accepted
by both surgeon and interventionist for either coronary
revascularization by surgery or PCI with stent implantation.
Patients were randomized in equal proportions to either
PCI or surgery. The trial’s pragmatic design required
operators to perform optimal revascularization according to
current local best practice. There were no specific require-
ments regarding procedural and postprocedural manage-
ment. Equivalent revascularization was encouraged but not
mandatory. The primary outcome was a comparison of the
rates of repeat revascularization between the two groups.
Secondary outcomes included a death and a composite of
death or nonfatal myocardial infarction (MI). A Clinical
Events Committee adjudicated all major outcomes. The
hazard ratio (HR) for repeat revascularization (PCI or
surgery), death, or Q-wave MI was estimated using a
proportional hazards model. Results. Between December
1996 and December 2000, a total of 988 patients were
randomized: surgery (n 5 500), PCI (n 5 488). The mean
(standard deviation) age for surgery was 61.5 (9.5) years, and
for PCI the mean was 61.3 (9.2) years. The baseline
characteristics were similar in both groups. Median
follow-up was two years. The rate of first repeat revascular-
ization after the index revascularization procedure of either
PCI or surgery was higher in the PCI group: 20% versus
6%. The HR was 3.9 (95% confidence interval [CI] 2.58 to
5.91), p , 0.001. The rate of death or Q-wave MI was
similar in both groups: PCI 9.2%, surgery 9.4%, HR 0.95
(95% CI 0.63 to 1.43), p 5 0.81.
COMMENTARY
The SoS trial is an important contemporary comparison
between multivessel stenting and surgery in patients who
require revascularization but are suitable candidates for
either technique. Although the rate of death or nonfatal MI
was similar in both treatment assignments, there was an
excess in the death rate for stenting: 4.1% versus 1.2%
favoring CABG, and 2.5% versus 0.8% at one year, also
significantly favoring CABG. This was attributed to the
potentially low mortality rate of CABG in the trial, but the
rate for first operation is fully in keeping with results at
many centers, such as the Cleveland Clinic. Another pos-
sibility was the imbalance in deaths from cancer—eight in
the stent group and one in the CABG group. Nevertheless,
this finding is quite troubling even though it was not
replicated in the Arterial Revascularization Therapies Study
(ARTS). The use of glycoprotein IIb/IIIa inhibitors was
extremely low in SoS, and this may have disadvantaged the
PCI/stent group patients. Furthermore, the primary out-
come of repeat target vessel revascularization was, as ex-
pected, in favor of CABG as well (62% vs. 6%, respectively).
In summary, in the SoS trial CABG prevailed over stenting,
but there are questions about the part that chance played in
excess mortality (a secondary but very important end point)
and about the state-of-the-art status of stenting with respect
to evidence-based, adjunct platelet inhibition.
ERIC J. TOPOL
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The Medicine, Angioplasty, or Surgery Study (MASS II)
Trial: A Randomized, Controlled Clinical Trial of Medical
Therapy, Coronary Angioplasty, or Bypass Surgery for
Multivessel Coronary Artery Disease
WHADY HUEB
HEART INSTITUTE UNIVERSITY OF SA˜O PAULO, BRAZIL
Background. Although percutaneous transluminal coro-
nary angioplasty (PTCA) and coronary artery bypass surgery
(CABG) are routinely used, there is no conclusive evidence
that these interventional methods offer greater benefit than
medical therapy (MT) alone. This study sought to evaluate
the relative efficacies of three possible therapeutic strategies
for patients with symptomatic multivessel coronary disease
and preserved ventricular function. Methods. A total of
7,783 (35.7%) patients with multivessel disease were
screened in a single institution, and 611 patients were
randomly assigned: 203 for CABG, 205 for PTCA, and 203
for MT. Enrollment required that complete revasculariza-
tion of at least two major vessels be deemed clinically
necessary and technically feasible for each interventional
strategy. The primary end point was the combined occur-
rence of unstable angina, myocardial infarction (MI), and
cardiac death. Results. Among the patients in the CABG
group, an average (6 SD [standard deviation]) of 3.1 6 0.8
vessels were grafted, and among those in the PTCA group,
1.9 6 0.7 were dilated. Stents were placed in .270% of the
patients in these two groups. Q-wave MI in relation to the
procedures was more frequent in the PTCA group (8.7%)
compared with 1.9% after CABG or 3.2% in MT, whereas
in-hospital mortality did not differ between the two groups
(2.5% in the CABG and 2.5% in the PTCA group). During
the first year of follow-up, additional interventions were
necessary in 8.2% of the patients in the PTCA group and
0.5% in the CABG group (p , 0.0001). Among the
patients in the MT group, 14 patients had CABG, eight
underwent PTCA, and four (2%) suffered cardiac death.
Both CABG and PTCA reduced anginal symptoms and
stress-induced ischemia considerably. Conclusions. Medi-
cal therapy alone was associated with a lower incidence of
primary end points. Surgical revascularization was superior
to medical therapy only in relation to the anginal status.
Patients treated with PTCA were more likely to require
further interventions than CABG patients.
COMMENTARY
This trial of 611 patients randomly assigned to surgery,
percutaneous intervention, or medical therapy was per-
formed in the modern stent era. Stents were placed in
approximately 70% of the patients. There was no apparent
difference in survival among the three therapies, although
both surgery and percutaneous intervention reduced anginal
symptoms and objective evidence of ischemia. Subsequent
interventions after enrollment were required in 11% of the
medically treated patients, 8.2% of the percutaneous inter-
vention patients, and 0.5% of the surgery patients.
SPENCER B. KING, III
Intracoronary Gamma Radiation for In-Stent Restenosis in
Saphenous Vein Grafts: A Multicenter Center Randomized
Clinical Study (SVG WRIST)
RON WAKSMAN, FOR
THE SVG WRIST INVESTIGATORS
WASHINGTON HOSPITAL CENTER, WASHINGTON, DC
Background. The Washington Radiation for In-Stent Re-
stenosis Trial for Saphenous Vein Grafts (SVG WRIST) is
a Food and Drug Administration–approved double-blinded
multicenter randomized trial in post–coronary bypass sur-
gery patients with diffuse in-stent restenosis (ISR) in their
saphenous vein grafts (SVG). This trial is the first study to
examine the effects of gamma radiation therapy on patients
with in-stent restenosis in bypass grafts. Methods. One
hundred and twenty patients with diffuse ISR in SVG
underwent percutaneous transluminal coronary angioplasty,
laser ablation or rotational atherectomy, and/or additional
stents. After the intervention, a noncentered closed-end
lumen catheter was positioned at the treated site, and
patients were randomly assigned to a ribbon either with
192-Ir or with nonradioactive seeds, both delivered by hand.
Different ribbon lengths of 6, 10, and 14 seeds with a mean
radiation length of 34 6 22 mm were used to cover lesion
lengths ,47 mm. The prescribed radiation doses were 14
Gy or 15 Gy to a 2 mm radial distance from the center of
the source for vessels with a diameter of 4 mm and 15 Gy at
2.4 mm for vessels .4 mm in diameter. A mean dwell time
of 22 6 7 min was tolerated well. Patients with restenosis at
follow-up were eligible to receive radiation if they had
initially been randomized to placebo. Results. The closed-
end lumen catheter with either the active or the placebo
seeds was delivered successfully to all patients. At 30 days,
there were no adverse events related to the radiation
therapy. At six months, the restenosis rate was significantly
lower in the irradiated group compared with the control
group (16% vs. 43%, p 5 0.004). The need for repeat
intervention at the treatment area was significantly reduced
by 79% in the irradiated group (10%) compared to the
control group (48%) (p 5 0.001), and the overall major
cardiac events were reduced by 20% in the irradiated group
compared with 55% in the control group (p 5 0.001). The
rate of late thrombosis in the irradiated group was 1.7%,
compared with 6.7% in the control group, and there was no
excess of edge effect in the irradiated group when compared
with the control group. Conclusions. Conventional treat-
ment of in-stent restenosis in bypass grafts is associated with
a high recurrence rate. The SVG WRIST study demon-
strated that catheter-based gamma radiation therapy for the
treatment of in-stent restenosis in bypass grafts is safe and
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effective in reducing the overall restenosis rate and the need
for repeat revascularization.
COMMENTARY
Endovascular radiation therapy has been shown to be
effective in significantly reducing the restenosis rate of ISR
in native coronary arteries. Saphenous vein grafts are larger,
and the restenosis process may not be identical to that in
native coronary arteries. This trial demonstrated that
endovascular radiation of SVGs that had been stented
was equally effective in preventing restenosis as radiation
was in native coronary arteries. The six-month restenosis
rate was 16%, compared with 43% in the control group,
and importantly, there was no excess late thrombosis
produced by the radiation. Radiation for ISR in vein
grafts, a most recalcitrant condition, now seems to have
an effective therapy.
SPENCER B. KING, III
ARRHYTHMIA/DEVICE TRIAL UPDATE
Prophylactic Use of Implantable Cardioverter-Defibrillators
in Patients With Idiopathic Dilated Cardiomyopathy: The
Cardiomyopathy Trial (CAT)
DIETMAR BA¨NSCH, MATTHIAS ANTZ,
SIGRID BOCZOR, MARIUS VOLKMER,
JU¨RGEN TEBBENJOHANNS, KARHEINZ SEIDL,
MALTE MEESMANN, MICHAEL BLOCK,
FRANK GIETZEN, JU¨RGEN BERGER, AND
KARL-HEINZ KUCK





UNIVERSITY HOSPITAL EPPENDORF, HAMBURG; AND
STADTISCHES KRANKENHAUS, BIELEFELD, GERMANY
Background. Patients with idiopathic dilated cardiomyop-
athy (DCM) and impaired left ventricular ejection fraction
(LVEF) have an increased risk of dying from ventricular
tachyarrhythmias (VTs). The prophylactic effect of an
implantable cardioverter defibrillator (ICD) in these pa-
tients was evaluated in a pilot trial. Methods. Patients with
recent-onset DCM (#9 months) and an LVEF #30% were
randomly assigned to ICD therapy or control. The primary
end point of the trial was all-cause one-year mortality.
Analysis was performed according to the intention-to-treat
principle. The trial was terminated after the inclusion of 104
patients because all-cause mortality rate was not reduced by
.26% in the ICD group after the first year of follow-up. In
August 2000, the vital status of all patients were updated by
contacting patients, relatives, or local registration offices.
Results. One hundred and four patients were enrolled in
the trial; 50 were assigned to ICD therapy, and 54 to the
control group. Mean follow-up was 22.8 6 4.3 months,
based on investigators’ follow-up, and 5.5 6 2.2 years, based
on the vital status collected by central data management in
Hamburg in August 2000. At two years, eight patients were
dead, four in each group. No sudden deaths occurred during
the first two years of follow-up. In August 2000, 30 deaths
had occurred, 13 in the ICD group and 17 in the control
group. There was no statistically significant difference in
cumulative survival between the two groups: 93% and 79%
in the control group versus 92% and 86% in the ICD group
after two years and four years, respectively. Implantable
cardioverter defibrillator therapy did not render a survival
benefit in any subgroup (i.e., patients with nonsustained VT
vs. patients without nonsustained VT). Conclusions. This
pilot trial did not provide any evidence in favor of a prophy-
lactic ICD implantation in patients with DCM of recent onset
and impaired LVEF without any further risk stratification.
This was possibly a consequence of the unexpectedly low
overall event rate and the small study population.
COMMENTARY
The CAT was undertaken as a pilot study to evaluate the
potential benefit on all-cause mortality of prophylactic ICD
implantation in patients with DCM. Idiopathic dilated
cardiomyopathy is undoubtedly the most vexing of condi-
tions with regard to risk stratification, largely because of the
reduced predictive accuracy associated with programmed
ventricular stimulation in afflicted patients. The trial was
terminated after the interim analysis in June 1997, because
no appreciable benefit of ICDs was observed after one year
of follow-up. This was likely due to the low overall mortality
represented by an unexpectedly low event rate for a condi-
tion traditionally associated with a high risk of sudden
cardiac death. It is also uncertain whether ICD therapy may
afford protection during even longer-term follow-up.
Clearly, more data will be required from other larger,
ongoing prospective randomized trials (e.g., Sudden Car-
diac Death-Heart Failure Trial [SCD-HeFT]) to make a
better definition of the optimal management of this ex-
tremely challenging subset of patients.
MARK SCHOENFELD
The Dual-Site Atrial Pacing for Prevention of Atrial
Fibrillation (DAPPAF) Trial: Improved Suppression of
Recurrent Atrial Fibrillation With Dual-Site Atrial Pacing
and Antiarrhythmic Drug Therapy
SANJEEV SAKSENA, ATUL PRAKASH,
PAUL ZIEGLER, JOHN D. HUMMEL,
PAUL FRIEDMAN, VANCE J. PLUMB,
D. GEORGE WYSE, ERIC JOHNSON,
STEPHANIE FITTS, AND RAHUL MEHRA, FOR
THE DAPPAF INVESTIGATORS
ATLANTIC HEALTH SYSTEM, PASSAIC, NJ
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Background. The DAPPAF trial examined the hypothesis
that dual-site right atrial pacing (DAP) is safe and will
result in further prolongation of time to recurrent symp-
tomatic atrial fibrillation (AF) and improve quality of life
compared with high right atrial pacing (HRAP) and sup-
port pacing (SP) in patients with recurrent symptomatic AF
and bradycardias in the presence or absence of antiarrhyth-
mic drug therapy. This prospective randomized clinical trial
enrolled 120 patients with bradycardias requiring cardiac
pacing and two or more episodes of electrocardiogram-
documented symptomatic AF in the three months before
enrollment. Patients were randomly assigned to DAP,
HRAP or SP for six-month periods after a two-week period
for optimization of drug and pacing therapies. They were
crossed over to the other arms either after completion of the
randomized phase or earlier if there were symptomatic AF
recurrences or adverse effects. Results. Adherence to pacing
mode was superior in DAP (mean duration 5.8 months)
when compared with SP (3.3 months, p , 0.001) or HRAP
(4.7 months, p 5 0.006) and in HRAP compared with SP
(p , 0.001). Adverse event-free survival was comparable in
DAP and HRAP, and DAP was superior to SP (p 5
0.007). The time to first symptomatic AF recurrence
trended to prolong with DAP (p 5 0.07, hazard ratio [HR]
0.715) but not with HRAP (p 5 0.18) when compared with
SP. In the presence of class 1 or 3 antiarrhythmic drugs,
DAP prolonged this interval compared with SP (p 5 0.011,
HR 0.638) and HRAP (p 5 0.06, HR 0.669). In drug-
treated patients with a baseline frequency of fewer than one
symptomatic AF event per week (Fig. 1), DAP was superior
to SP (p 5 0.004, HR 0.623) and HRAP (p 5 0.006, HR
0.46). Combined time to AF and adherence to pacing mode
events were superior in DAP compared with HRAP and SP
(p , 0.03 and p , 0.001, HRs 0.687 and 0.582, respec-
tively) with comparable safety. Conclusions. In patients
with frequent recurrent AF requiring pacing for bradycardia
and arrhythmia prevention, DAP, when combined with
class 1 or 3 antiarrhythmic drugs, is safe, better tolerated
and more effective than HRAP or SP.
COMMENTARY
The DAAPAF trial tested the hypothesis that DAP was
safe and would result in the prolongation of time to
recurrent AF and improve quality of life compared with
single-site HRAP or SP. This study was limited to 120
patients with recurrent symptomatic AF and bradycardia.
This trial demonstrated that DAP was beneficial (p 5 0.07)
in reducing the time to first symptomatic recurrence of AF
attacks compared with SP. In patients treated with concom-
itant antiarrhythmic medications, DAP was superior to
single-site HRAP (p 5 0.004) and SP (p 5 0.006) in
prolonging the interval to first attack. This trial suggests
that DAP as part of a hybrid therapy (along with antiar-
rhythmic medications) can be useful in decreasing the
frequency of AF attacks in patients with symptomatic AF
who have concomitant bradyarrhythmias (e.g., tachycardia-
bradycardia syndrome). These results are different from the
PA-3 trial, which showed no benefit from atrial pacing in
patients who did not have bradycardia or presumed
bradycardiac-aggravated, pause-dependent initiation of
their AF.
GERALD V. NACCARELLI
LATE-BREAKING CLINICAL TRIALS I
The Aggressive Diagnosis of Restenosis (ADORE) Trial
MARK J. EISENBERG
JEWISH GENERAL HOSPITAL, MONTREAL, CANADA
Background. Restenosis continues to be the major limita-
tion of percutaneous transluminal coronary angioplasty
(PTCA). To identify patients with restenosis, many physi-
cians routinely perform follow-up functional testing. It is
unclear which functional testing strategy is optimal: an
aggressive strategy of routine testing or a conservative
strategy of selective testing. Despite the fact that the
American College of Cardiology/American Heart Associa-
tion (ACC/AHA) guidelines for exercise testing suggest
that functional testing should not be performed routinely in
all post-PTCA patients, the ACC/AHA guidelines also
suggest that certain high-risk patients may benefit from
routine testing. There are few data to support these recom-
mendations, and there is thus little consensus on the
appropriate strategy to use. Although routine functional
testing will identify most patients with restenosis, this
Figure 1. Freedom from all symptomatic AF in each randomized pacing
mode in study population receiving concomitant class 1 or 3 antiarrhythmic
drugs with frequent (weekly events to two events in three months) AF at
baseline. Dual RA pacing shows prolongation of time interval to AF
recurrence as compared to high RA or support pacing in these patients.
Dual 5 dual site right atrial pacing; Single 5 high right atrial pacing;
Support 5 support pacing.
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strategy involves a high level of resource utilization, and its
clinical utility is unclear. By contrast, selective functional
testing may be associated with lower rates of follow-up
procedures but similar levels of functional status and quality
of life. Routine and selective functional testing strategies
have, to our knowledge, never been directly compared in a
prospective and randomized manner. Thus, the ADORE
trial was undertaken to directly compare functional status,
quality of life, and rates of cardiac procedures and clinical
events in patients randomized to routine versus selective
functional testing. Methods. The ADORE trial was an
international, multicenter, randomized clinical trial. A total
of 348 patients were randomized (172 to routine, and 176 to
selective functional testing) in 23 clinical centers in nine
countries. Patients in the routine functional testing arm
underwent a regular exercise treadmill test at 1.5 months
and an exercise treadmill test with nuclear perfusion imag-
ing at six months. By contrast, patients in the selective
functional testing arm underwent functional testing only if
they developed a clinical indication. The primary end point
of the study, functional status, was measured at nine months
by exercise endurance on an exercise treadmill test (METS).
Secondary end points were also evaluated at nine months
and included 1) the Duke Activity Status Index (DASI)
questionnaire; 2) the Seattle Angina Questionnaire (SAQ);
and 3) the SF-36 Health Survey. Composite end points of
cardiac procedures (cardiac catheterization, PTCA, CABG)
as well as clinical events (unstable angina, myocardial
infarction, death) were also evaluated at nine months.
Results. The majority of patients in the routine and
selective functional testing arms underwent single-vessel
PTCA (91% vs. 87%, respectively) with stent implantation
(86% vs. 82%, respectively). Among the patients random-
ized to routine functional testing, 23% had a positive
exercise treadmill test (ETT) at 1.5 months and 38% had a
positive ETT-nuclear at six months. Despite a more than
15-fold difference in the intensity of functional testing
between the two groups, exercise endurance (the primary
end point) was similar in the routine and selective groups
(METS: 9.9 6 2.7, 9.2 6 3.3, respectively, p 5 0.10).
Scores were similar on the DASI (44.3 6 11.3, 42.3 6 12.1,
p 5 NS), the five subscales of the SAQ, and the eight
subscales of the SF-36 Health Survey. Overall rates of
cardiac procedures were also similar in the routine and
selective groups (19% vs. 16%, respectively, p 5 0.40).
However, there was a trend for a higher rate of clinical
events in the routine group compared with the selective
group (17% vs. 8%, respectively, p 5 0.07). Conclusions.
We found little difference in functional status, quality of life,
and rates of clinical events among patients randomized to
routine versus selective functional testing after PTCA.
Thus, the results of the ADORE trial support the current
ACC/AHA guidelines, which do not recommend routine
functional testing in all post-PTCA patients. Because the
ADORE trial was under-powered to examine individual
high-risk subgroups, we believe further studies should
address whether routine functional testing can benefit spe-
cific high-risk groups of patients.
COMMENTARY
Some physicians perform functional testing routinely after
percutaneous coronary intervention (PCI) despite lack of
data supporting this approach. In this randomized trial of
348 patients, half the patients underwent routine testing
after the procedure while the other half underwent testing
based on clinical parameters. The clinical event rate (includ-
ing repeat cardiac procedures), quality of life, and functional
capacity were similar between the two groups. This study,
therefore, supports the ACC/AHA guidelines, which do
not recommend routine functional testing after PCI.
SANJIV KAUL
Angiogenic Gene Therapy (AGENT) Trial in Patients With
Stable Angina Pectoris
CINDY L. GRINES, MATTHEW W. WATKINS,
GREG HELMER, WILLIAM PENNY,
JEFFREY BRINKER, JONATHAN D. MARMUR,
ANDREW WEST, JEFFREY J. RADE,
H. KIRK HAMMOND, PRAN MARROTT, AND
ROBERT ENGLER
WILLIAM BEAUMONT HOSPITAL, ROYAL OAK, MICHIGAN
Background. Coronary revascularization procedures are
often limited by a lack of appropriate target vessels, early
graft failure, restenosis, and high cost. In an ameroid pig
myocardial ischemia model, myocardial gene transfer was
performed by intracoronary delivery of an adenovirus-
mediated fibroblast growth factor (Ad5-FGF-4). Successful
angiogenesis and improvement in regional blood flow and
ventricular function were observed. The presence of human
coronary collaterals has been associated with reduced isch-
emia, improved exercise tolerance, and reduced infarct size.
Therefore, growth factors that enhance collateral growth
may be of clinical benefit. Methods. To determine the
safety and anti-ischemic effect of Ad5-FGF-4 gene transfer
in humans, we performed a multicenter, randomized,
double-blind, placebo-controlled study of ascending doses
administered by a one-time intracoronary injection. Patients
ages 30 to 75 with stable exertional angina, who could
exercise on a treadmill for at least 3 min and whose
electrocardiogram showed an ST-segment depression
(.21 mm) were studied. Exclusion criteria included Type 1
diabetes, retinopathy, cancer, renal insufficiency, hepatic
disease, recent acute coronary syndrome or percutaneous
transluminal coronary angioplasty, left ventricular ejection
fraction ,30%, and severe proximal three-vessel coronary
disease. Patients underwent extensive baseline testing and
then were randomized 3:1 to gene therapy versus placebo.
Five ascending dose groups in one-half log steps were tested
(3.2 3 108 up to 3.2 3 1010 viral particles), administered by
subselective intracoronary injection of all major vessels.
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Numerous safety evaluations were conducted, and treadmill
testing for anti-ischemic effects was performed at four and
12 weeks. Results. A total of 79 patients were enrolled and
completed at least three months of follow-up (mean 311
days). There were no adverse events during Ad5-FGF-4
administration. Median first-pass extraction in the heart
was 87%, with greater viral detection in pulmonary artery
blood during intracoronary administration of higher doses.
In-hospital fever occurred in three (5%) patients, all in the
highest dose group. Other adverse events (e.g., rise in liver
enzymes) were infrequent and not related to dosing. There
was evidence of beneficial anti-ischemic effects compared
with placebo, with greater improvement in exercise duration
and more patients with substantial improvement (.30%
increase in exercise treadmill test [ETT]) in Ad5-FGF-4
treated groups. The greatest anti-ischemic effects were seen
in patients with more baseline impairment (ETT ,10 min)
and lower baseline neutralizing adenovirus antibody titers.
Conclusions. One-time intracoronary administration of
Ad5-FGF-4 was well tolerated, appeared to be safe, and
had evidence of beneficial anti-ischemic effects compared
with placebo.
COMMENTARY
Growth factor therapy for therapeutic angiogenesis, al-
though highly appealing, has been beset with substantial
challenges and uncertainties. The AGENT Trial appears to
represent a promising proof-of-principle experiment for
angiogenic gene therapy in the setting of stable coronary
artery disease. As presented by Dr. Cindy L. Grines, the
AGENT Trial assessed the safety and anti-ischemic effect
(using treadmill testing) of Ad5-FGF-4 gene transfer. Five
ascending doses covering a 2-log range of viral particle
concentration and administered by a single intracoronary
injection, were tested. The AGENT Trial suggested that
Ad5-FGF-4 exhibited an anti-ischemic benefit and was
safe. However, several limitations and caveats should be
noted, including the study’s small size and the lack of
radionuclide (or other confirmatory) demonstration of anti-
ischemic benefit. The occurrence of fever (highest dose
group) and the occasional rise in liver function tests suggest
a dosing limit and raise some concern for safety with
widespread clinical application. These concerns will need to
be addressed in future studies. The necessity to neutralize
antibodies to adenovirus was another limiting factor, at least
in some subjects. The enrollment of stable angina patients
was well suited to the study design, but in clinical practice,
Ad5-FGF-4 is likely to be applied primarily in patients with
advanced disease. Future studies may successfully establish a
dose regimen of Ad5-FGF-4 that is safe and effective, or
they may point to a different approach to angiogenic gene
therapy (e.g., a different vector, or a combination of two or
more growth factors that are synergistic in low doses).
Regardless, the AGENT Trial does add significantly to our
prior, limited experimental database and suggests that
growth factor gene therapy is feasible for human disease.
JEFFREY L. ANDERSON
Therapeutic Angiogenesis With Recombinant Fibroblast




R. DAVID ANDERSON, JORGE F. SAUCEDO,
ALAN N. TENAGLIA, JAMES B. HERMILLER,
WILLIAM HILLEGASS,
KRISHNA ROCHA-SINGH, THOMAS E. MOON,
M. J. WHITEHOUSE, AND BRIAN H. ANNEX,
FOR THE TRAFFIC INVESTIGATORS
NHLBI-NIH, BETHESDA, MD
Background. Recombinant fibroblast growth factor-2
(rFGF-2) improves perfusion in animal models of myocar-
dial and hindlimb ischemia. Preliminary human studies
indicate intra-arterial (IA) or intracoronary rFGF-2 infu-
sions of 30 mg/kg appear safe. In this randomized, double-
blind, placebo-controlled, multicenter trial, we address
whether IA infusion of rFGF-2 improves exercise capacity
in patients with moderate-to-severe intermittent claudica-
tion, and whether repeat administration of rFGF-2 after 30
days is superior to single administration of rFGF-2. Meth-
ods. Patients having moderate-to-severe intermittent clau-
dication attributable to infra-inguinal atherosclerosis, no
exercise-limiting comorbidity, reproducible treadmill per-
formance, and no theoretical contraindications to therapeu-
tic angiogenesis were randomized (1:1:1) into three groups.
All patients received either an IA study drug in both legs on
day 1 and again on day 30, placebo at both time points,
rFGF-2 followed by placebo (SINGLE group), or rFGF-2
twice (DOUBLE group). The primary end point was peak
walking time (PWT) on a Gardner treadmill protocol after
90 days. Secondary end points include ankle-brachial pres-
sure index, claudication onset time, quality of life, safety
after 90 and 180 days, and PWT after 180 days. Results.
Patients in the placebo group increased PWT by 0.6 min
(14%), patients in SINGLE increased PWT by 1.8 min
(34%, p 5 0.026 vs. placebo), and patients in DOUBLE
increased PWT by 1.5 min (20%, p 5 0.45 vs. placebo).
Analysis of variance (ANOVA) of evaluable patients
showed a p 5 0.075 for a difference among the three groups.
An alternative intention-to-treat ANOVA of ranks showed
a p 5 0.035. At 180 days, the increase peak walking time
persisted in patients receiving rFGF-2, however there was
an increase in placebo group PWT such that the groups
were no longer significantly different. There was no differ-
ence in claudication onset time among the three groups.
Ankle-brachial systolic blood pressure index increased in
patients receiving rFGF-2. Of the three prespecified sub-
groups (age, diabetes, and smoking), only current smoking
was a confounder. Regression modeling with adjustment for
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smoking status suggests that both SINGLE and DOUBLE
groups had a significant improvement in PWT compared
with placebo. Conclusions. A single IA infusion of
30 mg/kg of rFGF-2 results in .1 min improvement in
PWT over placebo at 90 days. A repeat IA infusion at 30
days is not better than a single IA infusion. Adjusting for
smoking status increases confidence in the effectiveness of
rFGF-2 treatment. After 180 days there is no difference in
PWT between placebo and rFGF-2 that was attributable to
placebo improvement. Intra-arterial rFGF-2 (30 mg/kg)
appears safe. The TRAFFIC Study is the first large,
randomized, placebo-controlled, therapeutic angiogenesis
study to show evidence of benefit in its primary efficacy
measure.
COMMENTARY
Therapeutic options for advanced peripheral vascular dis-
ease are greatly needed. Growth factor therapies, with either
genes or proteins, are being enthusiastically pursued, but
evidence for benefit from randomized trials of adequate size
has been lacking. The TRAFFIC Study tested rFGF-2-in
patients with moderate-to-severe intermittent claudication.
One or two IA doses (administered one month apart in both
legs) or placebo were administered, and PWT was reas-
sessed after three months and six months. As described by
Dr. Robert J. Lederman, the TRAFFIC Study is the first
randomized, placebo-controlled trial of moderate size to
show benefit for its primary efficacy measure. An almost
2-min improvement in exercise time occurred after three
months of rFGF-2 therapy compared with baseline. Also,
tolerability was excellent, and no significant safety concerns
were raised. However, several limitations and caveats should
be mentioned. The efficacy results were not robust when
compared with placebo. Indeed, one (intention-to-treat)
but not another (evaluable patients) analysis showed signif-
icant differences among groups. Of further concern, results
of secondary end points were not uniformly supportive of
benefit. For example, no differences were noted in time of
onset of claudication among the three groups. Also, no
dose-response was seen, even for PWT; indeed, the single-
but not double-dose regimen unexpectedly was demon-
strated to be beneficial. (Concern over this result was
somewhat alleviated by an analysis that adjusted for current
smoking status, which suggested benefit in both dosing
groups.) It is important to note that the advantage of
rFGF-2 was lost at six months because of a differential
improvement in the placebo group. This unexplained late
improvement in the placebo group, if believable, raises an
arguable question about the ultimate value of rFGF-2
therapy as administered in the patient population tested.
Although the TRAFFIC Study has not provided us with
definitive answers to a number of questions, it has added
substantially to our previously limited randomized database.
The TRAFFIC Study group is to be applauded for a
carefully designed study and for their valuable contribution
to our understanding of growth factor therapy for peripheral
vascular disease.
JEFFREY L. ANDERSON
A Placebo-Controlled Safety and Pharmacology Study of
ALT-711 in Older Patients With Stiffened Cardiovasculature
DAVID A. KASS,
FOR THE STUDY INVESTIGATORS
JOHNS HOPKINS HOSPITAL, BALTIMORE, MARYLAND
Background. ALT-711 is the first of a new pharmaceutical
class that catalytically breaks advanced glycosylation end-
product (AGE) crosslinks. Advanced glycosylation end-
product crosslinks accumulate with aging and diabetes,
particularly on long-lived proteins such as elastin and
collagen, increasing artery stiffness; and ALT-711 improves
distensibility in aged and diabetic animals. We tested the
effects of ALT-711 on blood pressure (BP) and vascular
distensibility in aged individuals with arterial stiffening in a
randomized, double-blind, placebo-controlled trial. Meth-
ods. Study participants at nine U.S. centers who had a
resting artery pulse pressure (PP) .60 mm Hg and systolic
pressure .140 mm Hg were randomly assigned to ALT-
711 (210 mg/day, n 5 63) or placebo (n 5 31) for eight
weeks. Existing antihypertensive medication was main-
tained in individuals under treatment. Morning fasting BP,
total arterial compliance and distensibility, pulse wave ve-
locity, stroke volume, cardiac output, and systemic vascular
resistance were assessed, along with drug safety and tolera-
bility. Results. Two patients dropped out of each group.
Pulse pressure declined significantly with eight weeks of
active treatment compared with placebo (25.6 vs.
20.5 mm Hg, p 5 0.024). Mean arterial pressure trended
downward slightly in both groups (2 to 5 mm Hg), but
neither systemic vascular resistance nor cardiac output was
altered. ALT-711 improved arterial compliance and disten-
sibility by 11% to 18% (p , 0.02 vs. placebo for both), and
the effect was significant after accounting for concomitant
changes in mean artery pressure. Conclusions. ALT-711
improves arterial distensibility in older patients with vascu-
lar stiffening. This may represent a novel therapeutic ap-
proach for patients with arterial stiffening associated with
aging, diabetes, and isolated systolic hypertension.
COMMENTARY
Arterial stiffening is seen with aging and some common
diseases, such as hypertension and diabetes. It manifests as
an increase in PP and systolic arterial pressure. This ran-
domized study evaluated the response of the aorta to a
member of a new class of drugs (ALT-711) that breaks
AGE crosslinks in older patients. Despite no change in
systemic vascular resistance or cardiac output, ALT-711
decreased PP compared with controls and also improved
arterial compliance and distensibility. Thus, this class of
drugs might offer a new therapeutic option for the reduction
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of arterial stiffening. Further studies are needed to deter-
mine whether this class of drugs affects outcome (hard
events, including death).
SANJIV KAUL
Effect of Clopidogrel in Acute Coronary Syndromes
SALIM YUSUF, FOR THE CURE (CLOPIDOGREL
IN UNSTABLE ANGINA TO PREVENT
RECURRENT EVENTS) TRIAL INVESTIGATORS
MCMASTER UNIVERSITY, HAMILTON, CANADA
Background. Despite current treatments, patients with
acute coronary syndromes (ACS) have high rates of major
vascular events. We evaluated the role of clopidogrel ad-
ministered for up to one year, in addition to aspirin, to ACS
patients. Methods. We randomized 12,562 patients with
ACS presenting ,224 h to receive clopidogrel (300 mg
immediately followed by 75 mg once daily) or placebo in
addition to aspirin for 3 to 12 months (mean, 9 months).
Results. Eleven and one-half percent of the placebo pa-
tients and 9.3% of the clopidogrel patients suffered the
primary outcome of cardiovascular death, myocardial infarc-
tion (MI), or strokes (relative risk [RR] 0.80, 95%; confi-
dence interval [CI] 0.72 to 0.89; p , 0.00005). The
co-primary outcome (primary 1 refractory ischemia) oc-
curred in 19% of placebo patients and 16.7% of clopidogrel
patients (RR 0.86, 95%; CI 0.79 to 0.94; p , 0.0005).
These benefits were statistically significant within 30 days,
and additional significant benefit accrued beyond this pe-
riod. The rates of in-hospital severe ischemia heart failure
and revascularization procedures were also significantly
reduced. There was an excess of major bleeds (2.7% placebo
vs. 3.6% clopidogrel, RR 1.34, p , 0.004) but no significant
excess in life-threatening bleeds (1.8% vs. 2.1%, p , 0.28)
or hemorrhagic strokes. Conclusions. Clopidogrel signifi-
cantly reduces the risk of cardiovascular death, MI, strokes,
and other related ischemic events, with an acceptable risk of
bleeding in ACS.
COMMENTARY
This randomized study of more than 12,000 patients eval-
uated the role of clopidogrel administered in addition to
aspirin in patients with ACS within 24 h of symptom onset.
The treatment was administered for a mean of nine months.
The patients receiving clopidogrel showed a 20% reduction
in cardiac events (death, MI and stroke) compared with
patients receiving placebo and aspirin. Benefit was seen early
and was cumulative over time. The major drawback was a
34% increase in major, but not life-threatening, bleeding.
Although the authors concluded that the risk of excess
bleeding was acceptable, clopidogrel should be used with
aspirin initially in high-risk patients with ACS only in cases
where the benefit would substantially outweigh the risk.
SANJIV KAUL
LATE-BREAKING CLINICAL TRIALS II
Mortality and Stroke Rates in a Trial of Rhythm Control
Versus Rate Control in Atrial Fibrillation: Results From the
STAF Pilot Phase (Strategies of Treatment of Atrial
Fibrillation)
JOERGE CARLSSON
KLINKUM LIPPE-DETMOLD, DETMOLD, GERMANY
Background. It is unclear how well a long-term strategy of
rhythm control compares with rate control in reducing
mortality and stroke in patients with atrial fibrillation (AF).
Methods. Patients with AF were randomized to either
rhythm control (cardioversion and antiarrhythmic therapy)
or rate control and anticoagulation. The primary composite
end points were death, cerebrovascular event, systemic
embolism, and cardiopulmonary resuscitation. To test the
assumed event rates, an analysis was planned after the first
200 patients, with a minimum follow-up of 12 months or a
primary end point (pilot phase). Results. Between January
1997 and January 1999, 200 patients were randomized (100
per group). The mean age did not differ between the two
groups (65.3 6 9.4 vs. 66.2 6 7.6 years; range 37 to 88
years). The mean follow-up was 19.5 6 8.9 versus 19.7 6
8.9 months (range 0 to 36 months and 1 to 36 months,
respectively). The duration of the arrhythmia was between
one and six months in most patients, with no differences
between the two groups. The most prevalent underlying
disease was hypertension in 62% of patients. Left atrial size
also did not differ between the groups (4.6 6 0.6 vs. 4.6 6
0.5 cm). The percentage of patients being in sinus rhythm in
the rhythm-control group (and rate-control group) was 70%
(2%) initially, 53% (14%) at one month, 46% (16%) at three
months, 49% (11%) at six months, 40% (12%) at 12 months,
34% (8%) at 18 months, 26% (11%) at 24 months, and 23%
(0%) at 36 months. Nine end points occurred in the
rhythm-control group, and 10 occurred in the rate-control
group (p 5 0.99). Four deaths occurred in the rhythm-
control group versus eight deaths in the rate-control group.
The rhythm at the event of an end point was sinus rhythm
in one patient and AF in 18 patients (p 5 0.049). Conclu-
sions. From the STAF pilot phase, four observations can be
made: 1) there was no difference between the two treatment
strategies regarding the composite primary end point; 2)
mortality in this patient cohort was low (3.67%/year), as
were cerebrovascular events (1.8%/year); 3) maintenance of
sinus rhythm was low, with 23% after three years despite
repeated cardioversions and antiarrhythmic therapy; and 4)
almost all events occurred in AF; only one occurred in sinus
rhythm (stroke after successful cardioversion).
COMMENTARY
Two aspects of the STAF trial pilot phase results are very
interesting. First, a surprisingly low proportion of patients
could be maintained in sinus rhythm even with antiarrhyth-
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mic therapy and several cardioversion attempts. If sinus
rhythm can be maintained in only about 40% of AF patients
using current techniques, then it will be difficult to demon-
strate any benefit with rhythm control in an unselected
group of these patients. Second, although the composite
event rates were similar for the rate control and rhythm
control groups, almost all events occurred during AF. It is,
however, possible that recurrent AF was only a marker of a
higher-risk subgroup. A much larger (4,000-patient) trial,
the Atrial Fibrillation: Follow-Up Investigation of Rhythm
Management (AFFIRM), is now in its final year and should
provide a more definitive estimate or the risks and benefits
of a rhythm-control strategy. However, even if there is no
difference in mortality or stroke in the AFFIRM trial, less
severe symptoms and quality-of-life issues, which will also
be reported by the AFFIRM trial, may yet make a rhythm-
control approach preferable in individual patients.
JOHN P. DIMARCO
Multicenter InSync Randomized Clinical Evaluation
(MIRACLE): Results of a Randomized, Double-Blind,
Controlled Trial to Assess Cardiac Resynchronization
Therapy in Heart Failure Patients
WILLIAM T. ABRAHAM, WESTBY G. FISHER,
ANDREW L. SMITH, DAVID B. DELURGIO,
EVAN LOH, DUSAN Z. KOCOVIC,
ALFREDO L. CLAVELL, DAVID L. HAYES,
STUART J. SMITH, AND ANTHONY S. L. TANG,
FOR THE MIRACLE INVESTIGATORS AND
COORDINATORS
UNIVERSITY OF KENTUCKY COLLEGE OF MEDICINE,
LEXINGTON, KENTUCKY
Background. Cardiac resynchronization therapy (CR) via
atrial-synchronized biventricular pacing has emerged as a
promising new treatment for heart failure (HF) patients
with intraventricular conduction delays or ventricular dysyn-
chrony. Initial studies demonstrated improved quality of life
(QOL) and functional capacity compared with baseline or
with no pacing. However, these studies were either uncon-
trolled or poorly controlled, unblinded or only single-
blinded; and they enrolled small numbers of patients.
Methods. The MIRACLE trial is the first prospective,
randomized, double-blind, controlled trial of CR in HF
that is adequately powered to assess functional end points
and QOL. Inclusion criteria were New York Heart Asso-
ciation (NYHA) class III or IV HF, left ventricular (LV)
ejection fraction (LVEF) ,235%, LV end diastolic diameter
(LVEDD) .255 mm, stable and optimal medical regimen,
and a QRS duration of .2130 ms without pacing indica-
tions. All patients were implanted with a CR system,
including a LV lead placed into a cardiac vein via the
coronary sinus. In the pivotal phase of the study, 300
patients were randomly assigned to either CR or no CR for
a period of six months to ensure follow-up of at least 225
patients through end-of-study testing. During controlled
evaluation, the electrophysiologist served as an unblinded
third party, while both the patient and managing HF
physician were kept blinded to the study assignment.
Change at six months in functional status as measured by
NYHA class, QOL questionnaire, and 6-min hall walk
distance comprised the primary efficacy end point of the
study. Primary safety measures included freedom from
device-, lead-, and system-related complications at six
months. Neurohormone levels, peak VO2, change in QRS
duration, echocardiographic indices of systolic and diastolic
cardiac structure and function, health care utilization, and
HF Clinical Composite Outcome were among the second-
ary end points. Results. Using a cutoff date of December 7,
2000, the first 244 patients completing six months of
follow-up comprise the population for this report. Baseline
demographics were age, 63.5 6 11 years; gender, 31%
female; race, 90% Caucasian; NYHA class, 91% class III;
QRS duration, 165 6 19 ms; LVEF, 22 6 6%; LVEDD,
69.5 6 9 mm. Study compliance was excellent, with ,2% of
patients undergoing unblinding or cross-over to alternative
therapy for worsening HF. Implant success rate was 93%.
Device, lead, and system safety exceeded all prespecified
levels of performance. Moreover, six-month mortality as-
sessed as a safety end point was identical in the two groups.
NYHA class, QOL, and 6-min hall walk were all signifi-
cantly improved in the CR compared with the control group
(combined p , 0.025). QRS duration was significantly
reduced in the CR group (165.6 6 18.6 to 148.2 6 22.7 ms,
p , 0.001) but not in the control group (164.5 6 20.5 to
159.6 6 27.5 ms, p 5 NS). Cardiac resynchronization
therapy also produced statistically significant improvements
in LV dimensions and function, peak VO2, health care
utilization, and HF clinical composite outcome, and it
significantly reduced plasma norepinephrine levels com-
pared with control. Conclusions. In patients with NYHA
class III or IV HF and intraventricular conduction delays,
CR is safe and improves functional capacity and QOL as
well as other measures of HF clinical status, cardiac perfor-
mance, and health care utilization.
COMMENTARY
Heart failure affects a large and rapidly growing segment of
the population. There have been recent reports of small
numbers of patients with severe HF who experienced
dramatic improvement in functional capacity and well-being
when treated with biventricular pacing, using a standard
dual-chamber pacemaker with an extra lead deployed in the
coronary venous system for simultaneous LV pacing. How-
ever, the implantation procedure is cumbersome, and not all
patients have shown improvement. The MIRACLE trial
was the first prospective, randomized, double-blind trial to
assess the safety and benefit of biventricular pacing in
patients with moderate-to-severe congestive HF. Initial
results, based on 244 patients with mean entry ejection
fraction 22 6 6%, showed that patients randomized to
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biventricular pacing realized significant improvement in
NYHA functional class, walking distance, and QOL, in
addition to decreases in LV dimension and health care
utilization. Complete system implantation, including LV
pacing lead, was successful in all but 7% of patients. Further
studies are needed to refine patient selection criteria and
optimal pacing site to achieve maximum improvement, but
these initial results clearly indicate the potential clinical
benefit of biventricular pacing for at least some patients with
moderate-to-severe HF.
JOHN M. MILLER
Effect of Carvedilol on Survival in Patients With Severe
Chronic Heart Failure (COPERNICUS)
MILTON PACKER, FOR THE COPERNICUS
STEERING COMMITTEE AND THE
COPERNICUS INVESTIGATORS AND
COORDINATORS
COLUMBIA UNIVERSITY, COLLEGE OF PHYSICIANS AND
SURGEONS, NEW YORK CITY, NEW YORK
Background. Previous trials of beta-blockers in heart fail-
ure (HF) have focused on patients with mild or moderate
symptoms. Experience with beta-blockers in patients with
symptoms at rest or on minimal exertion has been incon-
clusive or disappointing. The COPERNICUS study is the
first successful trial of a beta-blocker in severe HF. Meth-
ods. In an international double-blind, randomized, placebo-
controlled trial, 2,289 patients with symptoms at rest or on
minimal exertion with a left ventricular ejection fraction
,25% were randomly assigned to receive either carvedilol or
placebo in addition to appropriate background therapy for
HF. The trial did not enroll patients who were in the
intensive care unit, who had significant fluid retention, or
who had received intravenous treatment with a vasodilator
or positive inotropic drug within four days. Patients were
followed for up to 29 months, at which time the trial was
stopped by its ethical committee because of a marked
reduction in mortality. Results. Carvedilol reduced all-
cause mortality by 35% (p 5 0.00013) and decreased the
combined risk of all-cause mortality combined with hospi-
talization for any reason (by 24%, p 5 0.00004), for a
cardiovascular reason (by 23%, p 5 0.000023) or for HF (by
31%, p 5 0.000004). In addition, fewer patients in the
carvedilol group than in the placebo group were hospitalized
for HF (p 5 0.00011), for a cardiovascular reason (p 5
0.00034), or for any reason (p 5 0.0029). Patients treated
with carvedilol were not only less likely to be hospitalized at
least once but were less likely to be hospitalized multiple
times (p 5 0.021). When all causes of all hospitalizations
were considered, the carvedilol group had 20% fewer hos-
pitalizations for any reason (p 5 0.0017), 28% fewer
hospitalizations for a cardiovascular reason (p 5 0.0002),
and 33% fewer admissions for HF (p 5 0.0001). Patients in
the carvedilol group spent 27% fewer days in the hospital for
any reason than patients in the placebo group (p 5 0.0005).
This difference was attributable to both a decrease in the
total number of hospitalizations (p 5 0.0017) and a shorter
duration of each hospitalization (p 5 0.015). In addition,
while in the hospital, when compared with placebo-treated
patients, carvedilol-treated patients required fewer intrave-
nous treatments for HF (i.e., intravenous diuretics and
positive inotropic agents, p 5 0.001 and 0.001, respectively)
and fewer evaluations of ventricular function (by echocar-
diography, p 5 0.004). These observations indicate that
carvedilol not only reduced the frequency but also decreased
the severity of hospitalizations. Finally, patients in the
carvedilol group were less likely than those in the placebo
group to have experienced a serious adverse event (whether
or not death is included in the analysis) (p 5 0.0016 and
p 5 0.018, respectively). Carvedilol-treated patients were
more likely to report side effects related to the effects of
alpha- or beta-receptor blockade (e.g., bradycardia, dizzi-
ness, headache, hypotension, presyncope) (all p , 0.05). In
general, these were mild in severity and did not require
discontinuation of treatment. By contrast, placebo-treated
patients were more likely to experience major adverse
cardiac events that reflected the worsening of the underlying
cardiac disorder(s) (e.g., atrial fibrillation, cardiogenic
shock, HF, sudden death, supraventricular tachycardia,
ventricular fibrillation, ventricular tachycardia) (all p ,
0.05). In general, these were classified as severe and fre-
quently led to the withdrawal of double-blind treatment. It
is noteworthy that the most feared adverse event associated
with the use of beta-blockers in HF—worsening HF—was
reported less frequently in the carvedilol group than in the
placebo group (p 5 0.004). There was no increase in the risk
of worsening HF during initiation and uptitration of the
drug, despite the advanced severity of disease in the patients
in the study. Fewer patients required permanent discontin-
uation of treatment because of adverse effects or other reasons
(other than death) in the carvedilol group than in the placebo
group (p 5 0.020). Conclusions. In patients with severe
chronic HF, carvedilol not only reduced mortality but also
decreased the frequency and severity of hospitalization as well
as the utilization of health care resources. In addition, the drug
was well tolerated and was associated with fewer serious
adverse events. The benefits of carvedilol in this trial were
broad-based, clinically meaningful and cost-effective.
COMMENTARY
The use of beta-blockers in patients with mild-to-moderate
chronic HF has now been established, based on the results
of randomized controlled trials involving .10,000 patients.
However, current recommendations do not include patients
with severely symptomatic HF, because few such patients
have been studied. The COPERNICUS trial enrolled 2,289
patients with symptoms at rest or minimal activity and
ejection fraction #25%, although those with overt fluid
retention or recent treatment with intravenous diuretics or
positive inotropic drugs were excluded. The placebo group
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annual mortality rate of 19.7%, the highest in any beta-
blocker trial, is indicative of the severity of HF in this
population. The primary results of the COPERNICUS
trial, a highly significant 35% reduction in all-cause mor-
tality with carvedilol, have been presented previously and
recently appeared in the New England Journal of Medicine.
This presentation provided new information concerning the
effects of carvedilol on hospitalizations and adverse events,
which further confirmed the impressive benefit of treat-
ment. Remarkably, despite the severity of HF in these
patients, there was no evidence of an excess of clinical wors-
ening during the initiation of therapy. The results of the
COPERNICUS trial clearly demonstrate the importance of
using beta-blockers in patients with severe HF who are
well-treated and free of fluid retention. Approximately one life
can be saved for each 14 such patients treated for one year.
BARRY M. MASSIE
A Multinational, Randomized, Double-Blind Study on the
Effects of Carvedilol on Mortality and Morbidity in Patients
With Left Ventricular Dysfunction After Myocardial Infarc-
tion (CAPRICORN)
HENRY J. DARGIE, AND MEMBERS OF THE
CAPRICORN STEERING COMMITTEE, FOR
THE INVESTIGATORS AND COMMITTEES
UNIVERSITY OF GLASGOW, GLASGOW, UNITED KINGDOM
Background. The beneficial effects of beta-blockers on
long-term outcome after acute myocardial infarction (AMI)
were demonstrated before the introduction of thrombolysis
and angiotensin-converting enzyme (ACE) inhibitors and
before the widespread use of aspirin. We therefore investi-
gated the long-term efficacy of carvedilol on morbidity and
mortality in patients with left ventricular (LV) dysfunction
occurring after AMI that has been treated according to
current evidence-based practice, including a protocol re-
quirement for treatment with an ACE inhibitor. Methods.
In a multicenter double-blind, randomized, placebo-
controlled trial, 1,959 patients with a proven AMI and an
LV ejection fraction (LVEF) ,240% were randomly as-
signed to receive either carvedilol or placebo. Patients were
followed up until the requisite number of primary end
points had occurred. Analysis of the results was made by
intention to treat, using the log rank test for time to first
event. Results. Carvedilol reduced all-cause mortality by
23% (hazard ratio [HR] 0.77 [95% confidence interval 0.60
to 0.98], p 5 0.03) and all-cause mortality or cardiovascular
hospitalizations by 8% (HR 0.92 [0.08 to 1.07], p 5 0.30).
There were 26% fewer sudden deaths among patients being
treated with carvedilol (HR 0.74 [0.51 to 1.06], p 5 0.10),
while hospitalizations for heart failure (HF) fell by 14%
(HR 0.86 [0.67 to 1.09], p 5 0.21). Nonfatal myocardial
infarctions (MIs) fell by 41% (HR 0.59 [0.39 to 0.90], p 5
0.01), and all-cause mortality or nonfatal MI by 29% (HR
0.71 [0.57 to 0.89], p 5 0.002). Conclusions. In patients
treated long term for an AMI complicated by LV systolic
dysfunction with or without HF, carvedilol substantially
reduced the incidence of all-cause and cardiovascular mor-
tality and recurrent nonfatal MIs. These beneficial effects
are in addition to current evidence-based treatments for
AMI, including ACE inhibitors.
COMMENTARY
Although beta-blockers are now considered standard
post-MI therapy, the trials that led to this recommendation
were conducted before the widespread use of thrombolytic
agents or revascularization, aspirin, lipid-lowering agents,
and ACE inhibitors excluded patients with overt HF. The
CAPRICORN study evaluated carvedilol in 1,959 patients
3 to 21 days after MI with an LVEF ,240%, many of whom
received reperfusion therapy and nearly all of whom were
discharged with ACE-inhibitor therapy. Carvedilol treat-
ment was associated with statistically significant 23% and
41% reductions in all-cause mortality and recurrent nonfatal
MI, respectively. One death was prevented for each 43
patients treated for one year, a number similar to, but fully
additive to, that achieved with ACE-inhibitor therapy in
high-risk post-MI patients. Carvedilol was very well toler-
ated, with fewer hospitalizations for HF or withdrawals for
adverse reactions than placebo. The results of the CAPRI-
CORN study provide compelling new evidence for the use
of beta-blockers in post-MI patients with reduced ejection
fractions—a group who often are not treated but perhaps
stand to benefit most from these agents. [The primary
results of the CAPRICORN study were published on May
5, 2001, in the Lancet.]
BARRY M. MASSIE
A Prospective, Randomized, Double-Blind, Placebo-
Controlled, Multicenter Study of the Efficacy and Safety of
Tezosentan in Patients With Acute Decompensated Heart
Failure (RITZ 2)
GUILLERMO TORRE-AMIONE,
JAMES B. YOUNG, WILSON COLUCCI,
BASIL LEWIS, ISAAC KOBRIN, AND
CRAIG M. PRATT
METHODIST HOSPITAL, BAYLOR COLLEGE OF MEDICINE,
HOUSTON, TEXAS
Background. Acute decompensated heart failure (ADHF)
accounts for about one million hospitalizations in the U.S.
Current therapies for ADHF may rapidly reverse abnormal
hemodynamics; however, several drawbacks may limit their
use. The RITZ 2 study was designed to assess the efficacy
(hemodynamics and symptoms) and safety of tezosentan an
intravenous (IV) dual endothelin receptor antagonist in
patients with ADHF. Methods. This was a double-blind,
placebo-controlled multicenter study in which 292 patients
were randomized to receive either tezosentan 50 mg/h, or
100 mg/h, or placebo for 24 h. Eligible patients had to be
.218 years, with ADHF requiring IV treatment, and con-
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tinuous hemodynamic monitoring, for heart failure (HF).
Cardiac index (CI) and pulmonary capillary wedge pressure
(PCWP) had to be ,22.5 l/min/m
2 and .215 mm Hg,
respectively. Main exclusion criteria were systolic blood
pressure ,85 mm Hg, acute coronary syndrome, or percu-
taneous transluminal coronary angioplasty within the last
seven days. The primary end point was change from baseline
in CI at 6 h after start of treatment. The main secondary
end points included a change in other hemodynamic
parameters such as PCWP, pulmonary artery pressures
(PAPs), pulmonary vascular resistance (PVR), and systemic
vascular resistance (SVR) or a change in dyspnea assessment
by the patients at 6 h and 24 h, and time to death or
worsening of HF at 24 h. Results. Both doses of tezosentan
significantly improved CI and PCWP at 6 h compared with
placebo (Table 1). The effect was maintained for the whole
24 h of treatment and for at least 6 h after stopping
treatment. Similar effects were observed with regard to
PAPs, PVR and SVR. Treatment with tezosentan was
associated with a dose-related decrease in arterial pressure
and no change in heart rate. More patients treated with
tezosentan improved and fewer had worse dyspnea at 6 h
and 24 h (NS and p 5 0.048, respectively). In addition, a
clear tendency for an improvement in time to worsening of
HF or death was observed over the 24 h of treatment in the
patients receiving tezosentan (p 5 0.06) compared with
placebo. Compared with placebo, treatment with tezosentan
was associated with increased incidence of headache and, for
the 100 mg/h dose, symptomatic hypotension. No relevant
differences were observed between the treatment groups
regarding serious adverse events up to 28 days of follow-up.
Conclusions. Tezosentan significantly improves CI and
other cardiac hemodynamic parameters in patients with
ADHF. This effect was associated with an improvement in
clinical end points.
COMMENTARY
The RITZ-2 trial was the first of several trials evaluating the
dual endothelin A and B receptor antagonist tezosentan in
patients with acutely decompensated HF. This agent not
only is a potent vasodilator but also has the potential to
antagonize a number of other potentially deleterious actions
of this neurohormonal system. Two doses of tezosentan, 50
and 100 mg/h (after an initial 1-h infusion commencing at
25 mg/h), were compared with placebo, with a primary end
point of changes in hemodynamic measurements. Of note is
that hemodynamic measurements improved rapidly on the
25 mg dose, and the 50 and 100 mg doses produced almost
identical increases of approximately 20% in CI and reduc-
tions in PCWP. This hemodynamic response was accom-
panied by evidence of symptomatic improvement. However,
there were also higher incidences of headache, hypotension,
gastrointestinal symptoms, and declining renal function that
appeared to be dose-related. These findings indicate that
tezosentan offers a novel and potentially promising treat-
ment for this common condition, although lower doses may
provide a better ratio of benefit to risk. The subsequently
announced results of the RITZ-1 trial, which was designed
to evaluate symptoms in a similar population, provide
additional support for the need to evaluate lower doses of
tezosentan.
BARRY M. MASSIE
Better Long-Term Results After Stent Placement for Long
Coronary Artery Stenoses Guided by Intravascular Ultrasound
Compared to Angiography: Results of a Randomized Study
PRANOBE V. OEMRAWSINGH,
MARTIN J. SCHALIJ, AND
ERNST E. VAN DER WALL
LEIDEN UNIVERSITY MEDICAL CENTER,
LEIDEN, THE NETHERLANDS
Background. Percutaneous intervention for long coronary
lesions has a high rate of restenosis. In this study, we
compared the six-month angiographic results of AVE GFX
XL stent implantations in patients with stable angina, after
randomization for either intravascular ultrasound (IVUS)
guidance or use of angiography alone. Methods. Patients
with coronary stenoses .20 mm length and a reference
diameter allowing implantation of a stent with a diameter of
at least 3 mm were eligible. The IVUS criteria for optimal
stent placement were 1) complete stent apposition; 2)
minimal lumen diameter .80% of the mean of the proximal
and distal reference diameter; and 3) residual minimal
lumen area greater than distal reference area. Results. In
150 patients (46 women, 104 men; age 58 6 8 years), a total
of 187 stents with a length of 38 6 10 mm and a diameter
of 3.3 6 0.4 mm were implanted. Baseline demographic
data of both groups were comparable. Intravascular ultra-
sound was used in 73 (49%) procedures, and in 65 (89%) of
these all IVUS criteria were achieved. Follow-up angiogra-
phy at six months was available for 138 patients. Quantita-
tive analyses of the angiographic data of these patients are
shown in Table 2. Conclusions. Despite the use of more
and longer stents, the six-month angiographic outcome
after implantation of AVE GFX XL stents for long coro-
nary stenoses guided by IVUS was significantly better,
compared with implantation guided by angiography alone.






CI at BL 1.92 6 0.37 1.96 6 0.34 1.91 6 0.37
Change from BL 0.04 6 0.38 0.42 6 0.53* 0.41 6 0.56*
PCWP at BL 25.1 6 7.0 24.5 6 6.7 24.4 6 6.2
Change from BL 20.6 6 5.6 24.5 6 5.9* 24.6 6 6.0*
*p , 0.0001.
BL 5 baseline; CI 5 cardiac index; PCWP 5 pulmonary capillary wedge pressure.
607JACC Vol. 38, No. 3, 2001 DiMarco
September 2001:595–612 Late-Breaking Clinical Trials
COMMENTARY
This trial further supports the use of IVUS for optimal stent
implantation. Although the numbers are small, the IVUS
lesions tended to present more technical difficulties (signifi-
cantly longer, with more stents), with both greater short-term
gain and smaller post-stent lesion diameters, supporting the
use of IVUS to achieve maximal luminal results. As always, the
better the resultant lumen, the lower the restenosis. From a
practical standpoint, the application of IVUS potentially has its
greatest impact on less ideal lesions, particularly those involving
high-risk areas for restenosis, such as the proximal left anterior
descending. Thus, selective use of IVUS can potentially lower
restenosis by achieving optimal stent results.
GEORGE W. VETROVEC
LATE-BREAKING CLINICAL TRIALS III
Effect of Raloxifene on Serum Lipids and Clinical
Cardiovascular Events in Osteoporotic Postmenopausal
Women: Multiple Outcomes of Raloxifene Evaluation
(MORE)
ELIZABETH BARRETT-CONNOR,
DEBORAH GRADY, ANDREAS SASHEGYI,
PAMELA ANDERSON, DAVID A. COX, AND
KRISTINE D. HARPER
UNIVERSITY OF CALIFORNIA, SAN DIEGO;
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO;
LILLY RESEARCH LABORATORIES, INDIANAPOLIS, INDIANA
Background. An early increase in the risk of coronary heart
disease (CHD) events has been reported with hormone
replacement therapy in both secondary (Heart and Estro-
gen/progestin Replacement Study [HERS]) and primary
(Women’s Health Initiative [WHI]) prevention trials. The
objective of the MORE study was to assess the effects of
raloxifene (RLX), a selective estrogen receptor modulator
used for the prevention and treatment of osteoporosis, on
serum lipids and clinical cardiovascular events in postmeno-
pausal women with osteoporosis. Methods. The MORE
study randomized 7,705 osteoporotic postmenopausal
women to placebo or RLX (60 mg or 120 mg) daily for
three years. Total cholesterol was measured in all women;
lipoproteins and fibrinogen were measured in 2,738 women.
Cardiovascular events were collected as safety end points
and subsequently adjudicated by a cardiologist blinded to
therapy and not associated with the trial. Results. Com-
pared with placebo, RLX 60 mg/day significantly lowered
total cholesterol (26%), low-density lipoprotein cholesterol
(210%), and fibrinogen (210%) but did not increase
high-density lipoprotein cholesterol or triglycerides. Similar
results were observed with RLX 120 mg/day. The number
of coronary events (myocardial infarction, unstable angina,
or coronary ischemia), cerebrovascular events (stroke or
transient ischemic attack), or any cardiovascular event (cor-
onary 1 cerebrovascular) did not differ significantly between
treatment groups at three years or during the first year of
therapy (Table 3). Similar results were obtained in a
separate analysis of the 202 women who entered the study
with evidence of CHD and also when fatal and nonfatal
events were analyzed separately or individually by event
type. Conclusions. Raloxifene treatment for three years
improved cardiovascular risk factors. Although power was
limited, treatment with raloxifene was not associated with
either an early increase or an overall decrease in risk of
cardiovascular events in the MORE trial.
COMMENTARY
The MORE trial has demonstrated that treatment with the
selective estrogen modulator raloxifene for three years had
an overall beneficial effect on the measured cardiovascular
risk factors. The central question, with regard to cardiovas-
cular disease, is the degree to which this and/or other
actions of the agent affect the overall risk of clinical
events—both in patients with and in those without manifest
cardiovascular disease at the time treatment is initiated. In
this trial (in which most patients did not have recognized
cardiac disease at entry), the number of events was not large,
and the power was limited; but raloxifene treatment was not
Table 2. Angiographic Data
Baseline/Post-Stent/Follow-up
IVUS (n 5 73) No IVUS (n 5 77) p Value
Reference D (mm) 3.0 6 0.6/3.5 6 0.5/2.9 6 0.5 2.9 6 0.5/3.2 6 0.5/2.7 6 0.5 0.8/0.1/0.2
MLD (mm) 1.0/3.0/1.8 0.9/2.8/1.5 0.7/0.02/0.04
D stenosis (%) 66 6 14/13 6 6/38 6 14 65 6 10/12 6 9/45 6 21 0.8/0.6/0.04
Lesion length 29 6 10 27 6 9 0.3
Stent diameter 3.2 6 0.3 3.2 6 0.4 0.5
Number of stents 1.4 6 0.6 1.1 6 0.4 , 0.01
Stent length 42 6 11 35 6 11 0.02
Acute gain (mm) 2.0 6 0.6 1.8 6 0.4 0.04
Late loss (mm) 1.2 6 0.5 1.3 6 0.5 0.8
Loss index 0.7 0.7 0.4
Restenosis (n) 15 (20%) 28 (36%) 0.05
D 5 diameter; IVUS 5 intravascular ultrasound; MLD 5 minimal lumen diameter.
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associated with either a significant early increase or an
overall later decrease in the risk of cardiovascular events.
ERIC S. WILLIAMS
Safety and Efficacy of Subcutaneous Enoxaparin and
Streptokinase in Patients Presenting Acute Myocardial
Infarction: Results of the AMI-SK Trial
ANGELES ALONSO
CLI´NICA PUERTA DE HIERRO, MADRID, SPAIN
Background. Fibrinolytic treatment aims to restore coro-
nary perfusion in patients with acute myocardial infarction
(AMI). Streptokinase is an effective and widely used fi-
brinolytic agent. By contrast to tissue plasminogen activator
(tPA), heparin has not proven its efficacy as an adjunctive
therapy to streptokinase. However, reocclusion is fre-
quent—10% in hospital and 30% at three months—and this
may be prevented by anticoagulants. Methods. Patients
.18 years of age who presented suspected AMI of ,12 h of
the onset of symptoms and who were treated with strep-
tokinase (1.5 million U in 60 min) and aspirin (100 to
325 mg/day) were randomized to receive enoxaparin or
placebo. Enoxaparin was administered as a 30 mg intrave-
nous bolus followed by a 1 mg/kg subcutaneous injection
every 12 h for five to eight days. The median duration of
treatment in both groups was five days. The primary efficacy
end point was patency rate (Thrombolysis In Myocardial
Infarction [TIMI] 3) of the infarct-related artery assessed
with an angiogram between day 5 and day 10. Secondary
efficacy end points were early ST-segment resolution at
90 min and 180 min, and clinical outcome was the com-
posite of death, reinfarction, or angina during the 30 days of
follow-up. The primary safety parameter was the incidence
of major hemorrhagic episodes at 30 days follow-up. Re-
sults. Between June 1999 and July 2000, 496 patients were
recruited; 243 were assigned to receive placebo, and 253
received enoxaparin. Of all randomized patients, 99% were
treated, an angiogram was performed at some time in 86%,
and the percentage of evaluable patients (i.e., those treated
with an assessable angiogram performed within the time-
frame allowed) was 78%. There were no significant differ-
ences between the two groups with regard to baseline
characteristics: age, weight, gender, prior myocardial infarc-
tion (MI), anterior MI, smoking status, diabetes, hyperten-
sion, hypercholesterolemia, and time pain to streptokinase,
which was 2.8 h in the placebo group and 3.3 h in the
enoxaparin group. The primary efficacy end point revealed
an improved TIMI 3 flow of 70% with enoxaparin and 58%
with placebo (p , 0.001). Complete, partial or no ST-
segment resolution at 180 min was observed, respectively, in
36%, 44% and 19% in the enoxaparin group compared with
25%, 43% and 31% in the placebo group (p 5 0.004). The
triple clinical composite end point of death, reinfarction, or
angina was 13% with enoxaparin and 21% with placebo
(p 5 0.03). Major bleeding was observed in 4.8% of the
enoxaparin group compared with 2.8% in the placebo group
(p 5 0.2). Conclusions. Enoxaparin as adjunctive therapy
to streptokinase during five days is associated with 1) better
ST-segment resolution, suggesting better reperfusion; 2)
better angiographic patency from day 5 to day 10; and 3)
fewer clinical events, suggesting a lower reocclusion rate. All
of these associations occurred without a significant risk in
hemorrhagic episodes.
COMMENTARY
Although heparin therapy is clearly indicated when using
tPA or its congeners as a thrombolytic agent in AMI, the
use of heparin has not been shown to be efficacious when
employing streptokinase thrombolysis. The AMI-SK trial
randomized 496 patients receiving streptokinase and aspirin
therapy to receive placebo (n 5 243) or enoxaparin (n 5
253), a low-molecular weight heparin, administered every
12 h for five to eight days. The results strongly favored
enoxaparin therapy with enoxaparin-associated improve-
ments in TIMI 3 flow (70% vs. 58%, p , 0.001); increased
complete ST-segment resolution (p 5 0.004); and improve-
ment in the triple composite end point of death, reinfarc-
tion, and angina (p 5 0.03). Major bleeding was higher
with enoxaparin (4.8% vs. 2.8%), but this did not achieve
statistical significance (p 5 0.2). These results favor adding
enoxaparin to streptokinase thrombolysis for AMI. Al-
though there is a small increase in bleeding, and one should
be very cautious in any patient with a higher than normal
bleeding risk, the major clinical benefits of enhanced TIMI













Coronary Overall 39 34 43 0.88 (0.56–1.39) 1.10 (0.72–1.70)
Year 1 15 18 13 1.22 (0.62–2.41) 0.87 (0.42–1.83)
Cerebrovascular Overall 32 29 28 0.91 (0.55–1.50) 0.88 (0.53–1.45)
Year 1 8 7 10 0.89 (0.32–2.45) 1.26 (0.50–3.18)
Any CV event Overall 71 63 71 0.89 (0.64–1.25) 1.00 (0.72–1.39)
Year 1 23 25 23 1.10 (0.63–1.94) 1.01 (0.57–1.79)
CI 5 confidence interval; CV 5 cardiovascular; RLX 5 raloxifene (60 or 120 mg/d); RR 5 relative risk.
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flow and improved clinical end points strongly argue for the
use of enoxaparin in MI patients treated with streptokinase.
JOSEPH E. PARRILLO
The Pravastatin Inflammation/CRP Evaluation (PRINCE)
PAUL M. RIDKER, MICHELLE A. ALBERT,
ELLIE DANIELSON, JOAN E. STAGGERS,
AND PAUL H. CHEW, FOR THE PRINCE
INVESTIGATORS
CENTER FOR CARDIOVASCULAR DISEASE PREVENTION,
BRIGHAM AND WOMEN’S HOSPITAL,
HARVARD MEDICAL SCHOOL, BOSTON, MASSACHUSETTS;
AND BRISTOL MYERS SQUIBB, PLAINSBORO, NEW JERSEY
Background. Although elevated levels of plasma
C-reactive protein (CRP) predict cardiovascular risk and
retrospective studies suggest that statins lower CRP in a
largely low density lipoprotein-cholesterol (LDL-C) inde-
pendent manner, no prospective clinical trial data directly
evaluating this effect are available, particularly in primary
prevention where CRP screening, may have the greatest
utility. Methods. The PRINCE study included both a
randomized, double-blind trial of pravastatin 40 mg com-
pared with placebo among 1,339 men and women with no
prior history of cardiovascular disease (primary prevention
cohort) and an open-label evaluation of pravastatin 40 mg
among 898 patients with known cardiovascular disease
(secondary prevention cohort). None of the participants had
used a statin within the previous six months, and all of them
provided baseline, 12-week, and 24-week blood samples for
CRP and lipid evaluation. Results. In both the randomized
primary prevention and the open-label secondary prevention
cohorts, pravastatin reduced median CRP levels by 13%
(p , 0.001). No change in CRP was observed with placebo.
This effect was seen as early as 12 weeks (median reduction
in CRP with pravastatin 13.2%, p , 0.001) and was present
among all subgroups pre-specified by gender, age, smoking
status, body mass index, baseline lipid levels, and the
presence of diabetes. No association was seen between
baseline CRP and baseline LDL-C levels or between
end-of-study CRP and end-of-study LDL-C levels; conse-
quently, ,2% of the variance in CRP could be explained by
lipid levels. There was minimal evidence of association
between change in LDL-C and change in CRP, particularly
after adjustment for pravastatin use. No significant differ-
ences were observed between those in the primary and
secondary prevention cohorts in terms of CRP response.
Conclusions. In this prospective trial, pravastatin signifi-
cantly reduced CRP levels at both 12 weeks and 24 weeks.
These data confirm previous findings that pravastatin ther-
apy appears to have important anti-inflammatory effects.
COMMENTARY
Our present concept of the pathogenesis of atherosclerosis
recognizes the important role of the inflammatory process in
disease progression. The vascular wall is infiltrated by
macrophages, and cytokines and other inflammatory medi-
ators have been shown to have an important role in the
progression of atherosclerotic plaque. C-reactive protein is
an acute-phase response protein released by the liver into
the bloodstream in response to infection, trauma, and
inflammatory processes. Previous studies have demonstrated
that an elevated CRP (performed using a special, sensitive
assay that detects small elevations) is associated with an
increase in atherosclerotic cardiovascular events. The
PRINCE trial performed serial CRP blood levels in patients
who had begun to receive pravastatin for primary and
secondary prevention of cardiovascular atherosclerosis. The
results were exciting. Pravastatin reduced the median CRP
levels by 13% in both the primary and the secondary
prevention patients. The effects were evident by 12 weeks of
therapy. There was no association between the reductions in
CRP and decreases in LDL-C, making the authors argue
that ,2% of the variance in CRP could be explained by lipid
levels. The PRINCE data provide strong evidence that
pravastatin results in a substantial reduction in CRP, an
anti-inflammatory effect. This anti-inflammatory effect may
be very important in the anti-atherosclerotic, therapeutic effect
produced by statins. The ability of statins to reduce inflamma-
tion may account for their ability to reduce coronary events in
clinical trials of acute coronary syndromes at a point in time
before it could have begun to reduce serum LDL-C.
JOSEPH E. PARRILLO
Treat Angina With Aggrastatt and Determine Cost of
Therapy With an Invasive or Conservative Strategy
(TACTICS)-TIMI 18: Economic and Quality of Life Study
WILLIAM S. WEINTRAUB
EMORY UNIVERSITY, ATLANTA, GEORGIA
Background. There has been uncertainty in the treatment
of unstable angina and non-ST elevation myocardial infarc-
tion (MI) concerning the choice between an invasive strat-
egy using catheterization and revascularization and a con-
servative strategy in which invasive procedures are reserved
for patients with recurrent ischemia or positive functional
tests. There has also been a lack of economic data to
compare invasive and conservative approaches. This was
investigated in the TACTICS-TIMI 18 trial, in which
2,220 patients presenting with unstable angina or non-ST
segment elevation MI were treated with the glycoprotein
(GP) IIb/IIIa blocker tirofiban and then randomized to
either an invasive or a conservative strategy. In the invasive
strategy, catheterization was performed within 4 h to 48 h,
followed by revascularization if appropriate. In the conser-
vative strategy, catheterization was performed because of
recurrent ischemic episodes or a positive stress test. Tirofi-
ban (Aggrastat) was administered to all patients as an
intravenous loading infusion of 0.4 mg/kg per min over a
period of 30 min, followed by a maintenance infusion of
0.1 mg/kg per min from 48 h to 108 h, including $12 h
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after PCI. The primary composite end point of death, MI,
or rehospitalization for acute coronary syndrome at six
months was significantly reduced in the invasive strategy,
occurring in 15.9% of the invasive group compared with
19.4% of the conservative group (odds ratio 0.78, p 5
0.025). Methods. The hypothesis of the economic study
was that an invasive strategy would be equivalent in cost to
a conservative strategy over a period of six months. Costs
were measured for the initial hospitalization and the follow-
up. Initial and follow-up hospital costs were assessed in the
U.S. using the UB92 formulation of the hospital bill, with
charges reduced to cost by the hospital-specific cost-to-
charge ratio. Physician costs were estimated by using
diagnosis-related group-specific percent shares. Medication
costs were based on average wholesale price. Outpatient
costs, including office visits, testing, emergency room visits,
and ancillary care, were determined by the Medicare fee
schedule. Utility was determined by the Health Utilities
Index. Quality of life was measured with the Seattle Angina
Questionnaire. The cost-effectiveness design was intended
to measure cost per quality-adjusted life-year gained. Re-
sults. The in-hospital cost was higher in the invasive arm
($14,660 invasive vs. $12,667 conservative, a difference of
$1,994, 95% confidence interval [CI] $688 to $3,329).
However, follow-up costs were higher in the conservative
arm ($6,063 invasive vs. $7,203 conservative, a difference of
2$1,140, 95% CI 2$2,165 to 2$50). Thus, at six months,
a significant difference in cost was not noted ($20,616 invasive
vs. $19,987 conservative, a difference of $629, 95% CI
2$1,273 to $2,465). The minimal difference in cost made the
estimation of a cost-effectiveness ratio impossible. Angina
scores were initially low, but they improved dramatically in
both arms by six months. Conclusions. In patients presenting
with unstable angina or a non-ST segment elevation MI,
treated with GP IIb/IIIa blockade, the benefit of the invasive
strategy is achieved without a significant increase in cost.
COMMENTARY
This report extends the results of the TACTICS-TIMI-18
trial to include data about comparative costs of invasive and
conservative strategies for unstable angina/non-ST elevation
MI. Economic analyses of large multicenter trials can be
particularly difficult because of, for example, differences in
practice patterns and resource utilization beyond the
protocol-mandated procedures and also tests that can influ-
ence cost. Nonetheless, this carefully done, large study
supports the hypothesis that the higher up-front costs of an
invasive strategy are mitigated over the following six
months, when compared with a conservative strategy.
ERIC S. WILLIAMS
Program to Assess Alternative Treatment Strategies to
Achieve Cardiac Health (PATCH): EDTA Study
MERRIL L. KNUDTSON, D. GEORGE WYSE,
ROLLIN F. BRANT, P. DIANE GALBRAITH,
KATHY HILDEBRAND, DIANA PATERSON,
DEBORAH RICHARDSON, AND
CONNIE BURKART, FOR THE PATCH
INVESTIGATORS
UNIVERSITY OF CALGARY, CALGARY, ALBERTA, CANADA
Background. Ethylene diamine tetraacetic acid (EDTA)
or chelation therapy is an unproven “alternative” therapy
frequently sought by patients with ischemic heart disease.
This trial compared EDTA to placebo in patients with
proven ischemic heart disease and stable angina. Methods.
Randomized patients had 1-mm ST segment depression on
electrocardiogram between 2 min and 14 min on a gradually
increasing stress treadmill test. They were not candidates for
revascularization and had never had chelation therapy. All
patients received multivitamin supplements and optimal
medical management for angina. Therapy for reduction of
risk factors for ischemic heart disease was optimized. Either
EDTA or placebo was administered in a randomized,
double-blind fashion twice weekly for 15 weeks and then
once a month for a total of 33 treatments. The primary end
point was time to ischemia on treadmill testing. Secondary
end points included exercise functional reserve and quality-
of-life assessment. Primary and secondary end points and
clinical events were assessed at 30 weeks. Results. Three
thousand one hundred and forty patients were screened; 171
had a qualifying treadmill test, and 84 consenting patients
were randomized. Thirty-nine patients in each group com-
pleted the protocol. Time to ischemia at baseline was just
under 10 min in both groups. The mean increase in time to
ischemia at 30 weeks was 57.2 s (95% confidence interval [CI]
23.5 to 90.9, p 5 0.001) in the placebo group and 65.5 s (95%
CI 31 to 100, p 5 0.000) in the chelation group. The
difference was 8.3 s (95% CI 255.8 to 39.1, p 5 0.727).
Although there were modest improvements in both groups,
there were also no significant differences between groups with
respect to changes in secondary end points. There were no
deaths or myocardial infarctions. Three patients in the placebo
group and six in the chelation group were hospitalized for
worsening angina. One chelation therapy patient was with-
drawn from treatment for a rise in serum creatinine. Conclu-
sions. There is no evidence to support a beneficial effect of
chelation therapy in patients with ischemic heart disease with
stable angina and a positive treadmill test for ischemia.
COMMENTARY
Alternative or complementary medicine treatments encom-
pass a diverse group of approaches and therapies, many of
which are based on observational studies or reports. In the
PATCH trial, chelation therapy for patients with ischemic
heart disease was tested in a randomized, placebo-controlled
manner. This trial (albeit of modest size) provided no
evidence of clinical benefit of this unconventional treatment
in stable angina patients.
ERIC S. WILLIAMS
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Effects of Enrasentan, a Nonselective Endothelin Receptor
Antagonist, in Class II to III Heart Failure: Results of the
Enrasentan Cooperative Randomized (ENCOR) Evaluation
WILLIAM T. ABRAHAM, DEBORAH ASCHEIM,
THERESA DEMARCO, MARC KLAPHOLZ,
MARRICK KUKIN, ALAN MILLER,
LAURENCE YELLEN, TERRY L. HOLCSLAW,
AND MILTON PACKER, FOR THE ENCOR
INVESTIGATORS AND COORDINATORS
UNIVERSITY OF KENTUCKY COLLEGE OF MEDICINE,
LEXINGTON, KENTUCKY
Background. Elevated plasma endothelin (ET) correlates
with disease severity and is associated with poor prognosis in
patients with chronic heart failure (HF). Nonselective
ET-A/ET-B receptor antagonists and selective ET-A re-
ceptor antagonists are in HF trials. However, to date,
experience with these agents has been limited. Enrasentan is
an orally active, mixed ET-A/ET-B antagonist with a
100-fold greater selectivity for the ET-A receptor. Meth-
ods. The primary objective of this study was to compare the
effect of enrasentan with placebo on a composite measure of
clinical HF outcomes in patients with chronic New York
Heart Association (NYHA) class II or III HF. This
double-blind, randomized, positive and placebo-controlled
study included 419 men and women who were .218 years of
age, with stable HF for at least three months and left
ventricular ejection fractions (LVEFs) ,235%. Patients were
randomized to one of six treatment groups: 1) enrasentan
30 mg qd slow titration; 2) enrasentan 60 mg qd slow
titration; 3) enrasentan 60 mg qd normal titration; 4)
enrasentan 90 mg qd slow titration; 5) high-dose
angiotensin-converting enzyme (ACE) inhibitor; and 6)
placebo. Medication was titrated from a starting dose of 15
to 20 mg qd to the maximal tolerated doses of blinded
medication over a fixed 12-week period. Patients then
entered a six-month maintenance phase of follow-up. Back-
ground medications included stable doses of standard HF
drug therapy (diuretics, digoxin, ACE inhibitors, beta-
blockers) for at least one month. The primary end point was
a composite measure of HF clinical outcome, defined as
“improved” (improved NYHA class or global assessment),
“worsened” (death, worsening HF leading to hospitalization
or permanent withdrawal of therapy, or worsening of
NYHA class or global assessment), or “unchanged.” Sec-
ondary end points included individual components of the
composite measure as well as a time-to-event analysis of
death, HF hospitalization, or withdrawal because of wors-
ening HF. Results. Baseline demographics were mean age,
63 years; gender, 22.4% female; race, 75% Caucasian;
NYHA class, 51% class II; LVEF, 26 6 1%. Placebo
treatment resulted in an improved outcome for 45.9% of the
patients, whereas enrasentan treatment (all doses combined)
resulted in an improved outcome for only 38.7% of the
patients, as judged at the end of the study (p 5 0.0644,
trend favoring placebo). More patients in the enrasentan
treatment groups (27.8%) showed a worsening clinical HF
composite compared with the placebo group (17.2%); how-
ever, this difference did not reach statistical significance. A
comparable number of placebo patients (36.9%) had an
unchanged HF composite compared with enrasentan-
treated patients (34%). No enrasentan dose–response rela-
tionship was evident. The high-dose ACE-inhibition group
was comparable to the placebo-treatment group in the
percentage of patients whose HF composite end point was
judged to be improved, unchanged, or worsened. There
were more HF hospitalizations, cardiovascular hospitaliza-
tions, withdrawals because of worsening HF, and deaths in
the enrasentan-treated group than in the placebo group.
Time-to-event analyses of death, HF hospitalization, and
withdrawal because of worsening HF revealed a significantly
worse outcome for the enrasentan group than for either the
placebo group or the high-dose ACE-inhibition group.
Conclusions. In patients with class II or III HF, the
addition of the mixed endothelin receptor antagonist enra-
sentan to standard background therapy did not improve
clinical status, was associated with worsening clinical status
and outcome, and was not well tolerated. Treatment of
symptomatic HF with mixed endothelin receptor antago-
nists may not represent a safe and effective approach to
long-term treatment alternatives.
COMMENTARY
During the past decade, large clinical trials have demon-
strated the efficacy of direct-acting vasodilators
(hydralazine-isosorbide dinitrate), ACE inhibitors and
beta-blockers in reducing morbidity and mortality in mild
and moderate HF. Despite this progress, the mortality from
HF remains high. Endothelin is a potent endogenous
vasoconstrictor, and elevated blood endothelin levels have
been associated with poor prognosis in patients with chronic
HF. Thus, it is logical to hypothesize that inhibition of
endothelin would result in vasodilatation and improved
physiology in HF patients. This led to the ENCOR study,
which treated NYHA class II and III patients who were
receiving standard congestive HF therapy with one of four
dose regimens of enrasentan, a nonselective endothelin
receptor antagonist. The results were disappointing. The
primary end point, a composite end point defined as
“improved,” actually occurred more frequently in placebo
patients (46%) than in enrasentan patients (39%, p 5 0.06).
Other end points also favored placebo. Furthermore, no
dose-dependent response relationship was evident with
enrasentan. The ENCOR results show some clinical wors-
ening with the addition of enrasentan. This argues strongly
against the use of a nonselective endothelin receptor antag-
onist in HF patients.
JOSEPH E. PARRILLO
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